オランザピンの世界市場規模調査＆予測、用途別、投与経路別、流通チャネル別、地域別分析、2023-2030年

オランザピンの世界市場は2022年に約18億4,000万米ドルと評価され、予測期間2023-2030年には2.3%以上の健全な成長率で成長すると予測されています。

オランザピンは、主に統合失調症や双極性障害など、特定の精神疾患の治療に用いられる薬剤です。非定型抗精神病薬と呼ばれる薬剤クラスに属します。オランザピンは、ドーパミンやセロトニンといった脳内の特定の神経伝達物質のレベルに影響を与えることで作用します。これらの化学物質は、気分、思考、行動を調節する役割を担っています。オランザピン市場は、様々な地域における統合失調症の有病率の上昇、精神障害に対する施設を提供するための政府のイニシアチブの急増、様々な精神障害に関する消費者の意識の高まりなどの要因により拡大しています。

オランザピン市場は、神経疾患の頻度の増加や双極性障害における急性躁病の治療に対する需要の増加により拡大しています。世界の人口が年間1％以上のペースで増加し、人々が十分なニュートリノを受けていないため、統合失調症などの疾患が増加しています。ライフスタイルの変化や仕事や生活上のストレスの増加の結果、感情的・精神的疾患の有病率が上昇しており、これがオランザピン市場の有利な成長を促進すると予想されています。米国国立精神衛生研究所（NIH）によると、米国では2020年に5,290万人の成人が精神疾患を経験しています。その結果、精神疾患の治療にオランザピン製剤の使用が必要となる精神疾患を患う人が増加し、市場の成長を後押ししています。さらに、2022年の世界保健機関（WHO）のデータによると、世界では8人に1人が精神疾患を患っています。さらに、いくつかの地域では、オランザピン新薬への投資を拡大するイニシアチブが強まっています。このイニシアチブは、オランザピン市場に新たな開拓の機会をもたらす傾向にあります。しかし、オランザピンの高コストとその副作用は、2023年から2030年の予測期間を通じて、オランザピン市場の拡大の妨げとなっています。

オランザピンの世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカなどです。北米は、同地域における統合失調症などの精神疾患の有病率の上昇、高い保険普及率と医療施設、同地域における主要企業の地理的拡大、有利な規制要件などの要因により、2022年の市場を独占しました。アジア太平洋地域は予測期間中に大きく成長すると予想されます。これは、健康的なライフスタイルを奨励する政府の取り組みが増加していることに起因しています。さらに、同地域ではオランザピン医薬品を販売する薬店や小売薬局が増加していることも市場成長に寄与しています。

本調査の目的は、近年におけるさまざまなセグメントおよび国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 オランザピンの世界市場の定義と範囲

• 調査目的
• 市場の定義と範囲
  • 産業の進化
  • 調査範囲
• 調査対象年
• 通貨換算レート

第3章 オランザピンの世界市場力学

• オランザピン市場の影響分析（2020-2030年）
  • 市場促進要因
    • 世界の統合失調症有病率の上昇
    • 精神疾患に対する政府の取り組みの急増
    • 精神疾患に対する消費者の意識の高まり
  • 市場の課題
    • オランザピンの高コスト
    • 製剤による副作用
  • 市場機会
    • オランザピン製剤の進歩
    • 精神疾患の増加

第4章 世界のオランザピン市場産業分析

• ポーターのファイブフォースモデル
• ポーターのファイブフォース影響分析
• PEST分析
• 主な投資機会
• 主要成功戦略
• COVID-19影響分析
• 破壊的動向
• 業界専門家の視点
• アナリストの提言・結論

第5章 オランザピンの世界市場：用途別

• 市場スナップショット
• オランザピンの世界市場：用途別実績 - ポテンシャル分析
• オランザピンの世界市場：用途別推定・予測 2020-2030年
• オランザピン市場：サブセグメント別分析
  • 統合失調症
  • 双極性障害
  • その他

第6章 オランザピンの世界市場：投与経路別

• 市場スナップショット
• オランザピンの世界市場：投与経路別、実績 - ポテンシャル分析
• オランザピンの世界市場：投与ルート別推定・予測 2020-2030年
• オランザピン市場：サブセグメント別分析
  • 経口
  • 非経口

第7章 オランザピンの世界市場：流通チャネル別

• 市場スナップショット
• オランザピンの世界市場：流通チャネル別、実績 - ポテンシャル分析
• オランザピンの世界市場：流通チャネル別推定・予測 2020-2030年
• オランザピン市場：サブセグメント分析
  • 病院薬局
  • ドラッグストアおよび小売薬局
  • オンラインプロバイダー

第8章 オランザピンの世界市場：地域別分析

• 主要国
• 主な新興国
• オランザピン市場、地域別市場スナップショット
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • メキシコ
• 中東・アフリカ
  • サウジアラビア
  • 南アフリカ
  • その他中東とアフリカ

第9章 競合情報

• 主要企業のSWOT分析
• 主要市場戦略
• 企業プロファイル
  • Bristol-Myers Squibb Company
    • 主要情報
    • 概要
    • 財務（データの入手可能性によります）
    • 製品概要
    • 最近の動向
  • Dr. Reddy's Laboratories Ltd
  • Endo International plc
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Mylan N.V.
  • Novartis AG
  • Lupin Ltd.
  • Cipla Inc
  • Eli Lily and Company
  • Research Process
• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • 検証
  • 出版
• 調査属性
• 調査前提条件

LIST OF TABLES

• TABLE 1. Global Olanzapine Market, report scope
• TABLE 2. Global Olanzapine Market estimates & forecasts by Region 2020-2030 (USD Billion)
• TABLE 3. Global Olanzapine Market estimates & forecasts by Application 2020-2030 (USD Billion)
• TABLE 4. Global Olanzapine Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
• TABLE 5. Global Olanzapine Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
• TABLE 6. Global Olanzapine Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 7. Global Olanzapine Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 8. Global Olanzapine Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 9. Global Olanzapine Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 10. Global Olanzapine Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 11. Global Olanzapine Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 12. Global Olanzapine Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 13. Global Olanzapine Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 14. Global Olanzapine Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 15. Global Olanzapine Market by region, estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 16. U.S. Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 17. U.S. Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 18. U.S. Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 19. Canada Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 20. Canada Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 21. Canada Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 22. UK Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 23. UK Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 24. UK Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 25. Germany Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 26. Germany Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 27. Germany Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 28. France Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 29. France Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 30. France Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 31. Italy Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 32. Italy Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 33. Italy Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 34. Spain Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 35. Spain Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 36. Spain Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 37. RoE Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 38. RoE Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 39. RoE Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 40. China Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 41. China Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 42. China Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 43. India Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 44. India Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 45. India Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 46. Japan Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 47. Japan Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 48. Japan Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 49. South Korea Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 50. South Korea Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 51. South Korea Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 52. Australia Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 53. Australia Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 54. Australia Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 55. RoAPAC Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 56. RoAPAC Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 57. RoAPAC Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 58. Brazil Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 59. Brazil Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 60. Brazil Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 61. Mexico Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 62. Mexico Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 63. Mexico Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 64. RoLA Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 65. RoLA Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 66. RoLA Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 67. Saudi Arabia Olanzapine Market estimates & forecasts, 2020-2030 (USD Billion)
• TABLE 68. South Africa Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 69. RoMEA Olanzapine Market estimates & forecasts by segment 2020-2030 (USD Billion)
• TABLE 70. List of secondary sources, used in the study of global Olanzapine Market
• TABLE 71. List of primary sources, used in the study of global Olanzapine Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

• FIG 1. Global Olanzapine Market, research methodology
• FIG 2. Global Olanzapine Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Olanzapine Market, key trends 2022
• FIG 5. Global Olanzapine Market, growth prospects 2020-2030
• FIG 6. Global Olanzapine Market, porters 5 force model
• FIG 7. Global Olanzapine Market, pest analysis
• FIG 8. Global Olanzapine Market, value chain analysis
• FIG 9. Global Olanzapine Market by segment, 2020 & 2030 (USD Billion)
• FIG 10. Global Olanzapine Market by segment, 2020 & 2030 (USD Billion)
• FIG 11. Global Olanzapine Market by segment, 2020 & 2030 (USD Billion)
• FIG 12. Global Olanzapine Market by segment, 2020 & 2030 (USD Billion)
• FIG 13. Global Olanzapine Market by segment, 2020 & 2030 (USD Billion)
• FIG 14. Global Olanzapine Market, regional snapshot 2020 & 2030
• FIG 15. North America Olanzapine Market 2020 & 2030 (USD Billion)
• FIG 16. Europe Olanzapine Market 2020 & 2030 (USD Billion)
• FIG 17. Asia pacific Olanzapine Market 2020 & 2030 (USD Billion)
• FIG 18. Latin America Olanzapine Market 2020 & 2030 (USD Billion)
• FIG 19. Middle East & Africa Olanzapine Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

Global Olanzapine Market is valued at approximately USD 1.84 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 2.3% during the forecast period 2023-2030. Olanzapine is a medication used to treat certain mental health conditions, primarily schizophrenia and bipolar disorder. It belongs to a class of drugs called atypical antipsychotics. Olanzapine works by affecting the levels of certain neurotransmitters in the brain, such as dopamine and serotonin. These chemicals play a role in regulating mood, thoughts, and behavior. The Olanzapine Market is expanding because of factors such as the rising prevalence of schizophrenia in various regions, the surge in government initiatives to provide facilities for mental disorders and increasing consumer awareness regarding various mental disorders.

The Olanzapine Market is growing due to an increase in the frequency of neurological illnesses and a greater demand for the treatment of acute mania in bipolar disorders. Diseases such as schizophrenia are on the rise as the world's population grows at a pace of more than 1% per year, and people aren't receiving enough neutrinos. The prevalence of emotional and mental illnesses is rising as a result of changing lifestyles and increased job and life stress, which is expected to drive lucrative growth in the Olanzapine Market. According to the National Institute of Mental Health (NIH), 52.9 million adults in the United States experienced mental illness in 2020. As a result, an increase in the number of people suffering from mental illnesses that necessitate the use of olanzapine medicine to treat the condition drives market growth. Furthermore, according to World Health Organization (WHO) data in 2022, 1 out of every 8 individuals worldwide suffers from a mental condition. Additionally, in several regions, initiatives to expand investment in new Olanzapine medications are intensifying. This initiative tends to open up new development opportunities for the Olanzapine Market. However, the high cost of olanzapine and its adverse effects hampers the expansion of the Olanzapine Market throughout the forecast period of 2023-2030.

The key regions considered for the Global Olanzapine Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the factors such as the rising prevalence of mental diseases such as schizophrenia in the region, high insurance penetration and medical facilities, geographical expansion of key players in the region and favorable regulatory requirements. Asia Pacific is expected to grow significantly over the forecast period. This is attributed to increased government efforts to encourage a healthy lifestyle. Furthermore, the increasing number of medication stores and retail pharmacies selling olanzapine pharmaceuticals in the region contributes to market growth.

Major market player included in this report are:

• Bristol-Myers Squibb Company
• Dr. Reddy's Laboratories Ltd
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Mylan N.V.
• Novartis AG
• Lupin Ltd.
• Cipla Inc
• Eli Lily and Company

Recent Developments in the Market:

• In November 2023, Royalty Pharma plc and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., have revealed a collaboration aimed at expediting the clinical research program for Teva's olanzapine LAI (TEV-'749). This collaboration involves a funding agreement valued at USD 125 million to cover program costs. This funding arrangement allowed company to continue to advance the development of olanzapine LAI (TEV-'749), a vital initiative for Teva Pharmaceuticals, while preserving the company's resources for more advanced and futuristic formulations.
• In October 2023, Coya Therapeutics, Inc., and Dr. Reddy's Laboratories formed an exclusive collaboration to develop and commercialize COYA 302, an investigational combination therapy for ALS.
• In April 2023, CHEPLAPHARM announced that it had reached an agreement with Eli Lilly and Company to acquire the worldwide commercial rights to Zyprexa. The deal concerns the well-established and well-positioned olanzapine/olanzapine pamoate monohydrate ("OPM") portfolio, which includes ZypAdhera / Relprevv (depot IM [2]), Zyprexa IM2 (IM), Zyprexa Zydis / Zyprexa Velotab (ODT form), and Zyprexa (oral form, tablets). This acquisition strengthens the company's portfolio in the therapeutic field of the central nervous system and marks another milestone in CHEPLAPHARM's success story.

Global Olanzapine Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Application, Route of Administration, Distribution Channel, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Application:

• Schizophrenia
• Bipolar Disorder
• Others

By Route of Administration:

• Oral
• Parenteral

By Distribution Channel:

• Hospital Pharmacies
• Drug stores and Retail Pharmacies
• Online Providers

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1. Olanzapine Market, by Region, 2020-2030 (USD Billion)
  • 1.2.2. Olanzapine Market, by Application, 2020-2030 (USD Billion)
  • 1.2.3. Olanzapine Market, by Route of Administration, 2020-2030 (USD Billion)
  • 1.2.4. Olanzapine Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Olanzapine Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Industry Evolution
  • 2.2.2. Scope of the Study
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Olanzapine Market Dynamics

• 3.1. Olanzapine Market Impact Analysis (2020-2030)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising prevalence of schizophrenia worldwide
    • 3.1.1.2. Surge in government initiatives for mental disorders
    • 3.1.1.3. Increasing consumer awareness regarding mental diseases
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Olanzapine
    • 3.1.2.2. Adverse effects of formulations
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Advancements in olanzapine formulations
    • 3.1.3.2. Rising mental illness

Chapter 4. Global Olanzapine Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Porter's 5 Force Impact Analysis
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
  • 4.3.5. Environmental
  • 4.3.6. Legal
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. COVID-19 Impact Analysis
• 4.7. Disruptive Trends
• 4.8. Industry Expert Perspective
• 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Olanzapine Market, by Application

• 5.1. Market Snapshot
• 5.2. Global Olanzapine Market by Application, Performance - Potential Analysis
• 5.3. Global Olanzapine Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 5.4. Olanzapine Market, Sub Segment Analysis
  • 5.4.1. Schizophrenia
  • 5.4.2. Bipolar Disorder
  • 5.4.3. Others

Chapter 6. Global Olanzapine Market, by Route of Administration

• 6.1. Market Snapshot
• 6.2. Global Olanzapine Market by Route of Administration, Performance - Potential Analysis
• 6.3. Global Olanzapine Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 6.4. Olanzapine Market, Sub Segment Analysis
  • 6.4.1. Oral
  • 6.4.2. Parenteral

Chapter 7. Global Olanzapine Market, by Distribution Channel

• 7.1. Market Snapshot
• 7.2. Global Olanzapine Market by Distribution Channel, Performance - Potential Analysis
• 7.3. Global Olanzapine Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 7.4. Olanzapine Market, Sub Segment Analysis
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Drug stores and Retail Pharmacies
  • 7.4.3. Online Providers

Chapter 8. Global Olanzapine Market, Regional Analysis

• 8.1. Top Leading Countries
• 8.2. Top Emerging Countries
• 8.3. Olanzapine Market, Regional Market Snapshot
• 8.4. North America Olanzapine Market
  • 8.4.1. U.S. Olanzapine Market
    • 8.4.1.1. Application breakdown estimates & forecasts, 2020-2030
    • 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
    • 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 8.4.2. Canada Olanzapine Market
• 8.5. Europe Olanzapine Market Snapshot
  • 8.5.1. U.K. Olanzapine Market
  • 8.5.2. Germany Olanzapine Market
  • 8.5.3. France Olanzapine Market
  • 8.5.4. Spain Olanzapine Market
  • 8.5.5. Italy Olanzapine Market
  • 8.5.6. Rest of Europe Olanzapine Market
• 8.6. Asia-Pacific Olanzapine Market Snapshot
  • 8.6.1. China Olanzapine Market
  • 8.6.2. India Olanzapine Market
  • 8.6.3. Japan Olanzapine Market
  • 8.6.4. Australia Olanzapine Market
  • 8.6.5. South Korea Olanzapine Market
  • 8.6.6. Rest of Asia Pacific Olanzapine Market
• 8.7. Latin America Olanzapine Market Snapshot
  • 8.7.1. Brazil Olanzapine Market
  • 8.7.2. Mexico Olanzapine Market
• 8.8. Middle East & Africa Olanzapine Market
  • 8.8.1. Saudi Arabia Olanzapine Market
  • 8.8.2. South Africa Olanzapine Market
  • 8.8.3. Rest of Middle East & Africa Olanzapine Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Company 1
  • 9.1.2. Company 2
  • 9.1.3. Company 3
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Bristol-Myers Squibb Company
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Recent Developments
  • 9.3.2. Dr. Reddy's Laboratories Ltd
  • 9.3.3. Endo International plc
  • 9.3.4. Teva Pharmaceutical Industries Ltd
  • 9.3.5. Sun Pharmaceutical Industries Ltd
  • 9.3.6. Mylan N.V.
  • 9.3.7. Novartis AG
  • 9.3.8. Lupin Ltd.
  • 9.3.9. Cipla Inc
  • 9.3.10. Eli Lily and Company
  • 9.3.11. Research Process
• 9.4. Research Process
  • 9.4.1. Data Mining
  • 9.4.2. Analysis
  • 9.4.3. Market Estimation
  • 9.4.4. Validation
  • 9.4.5. Publishing
• 9.5. Research Attributes
• 9.6. Research Assumption